6tpd - Revision history

OCA at 13:06, 24 January 2024

OCA — Wed, 24 Jan 2024 13:06:40 GMT

←Older revision		Revision as of 13:06, 24 January 2024
Line 3:		Line 3:
	<StructureSection load='6tpd' size='340' side='right'caption='[[6tpd]], [[Resolution\|resolution]] 1.99Å' scene=''>		<StructureSection load='6tpd' size='340' side='right'caption='[[6tpd]], [[Resolution\|resolution]] 1.99Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6tpd]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TPD OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=6TPD FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6tpd]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TPD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TPD FirstGlance]. <br>
-	</td></tr><tr id='~~ligand~~'><td class="sblockLbl"><b>[[~~Ligand~~\|~~Ligands~~:]]</b></td><td class="sblockDat" id="~~ligandDat~~">~~<scene name='pdbligand=QZ8:3~~-~~methyl-4-phenyl-2~~,~~7-dihydropyrazolo~~[~~3,4-b~~]~~pyridin-6-one'>QZ8</scene>~~</td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.99Å</td></tr>
-	<tr id='~~gene~~'><td class="sblockLbl"><b>[[~~Gene~~\|~~Gene~~:]]</b></td><td class="sblockDat"~~>JAK2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&~~id~~=9606 HUMAN])</td></tr>~~	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=QZ8:3-methyl-4-phenyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one'>QZ8</scene></td></tr>
-	~~<tr id='activity'><td class~~="~~sblockLbl~~"><~~b>Activity:</b></td><td class~~=~~"sblockDat"><span class~~=~~'plainlinks'>[http~~:~~//en.wikipedia.org/wiki/Non~~-~~specific_protein~~-~~tyrosine_kinase Non~~-~~specific protein~~-~~tyrosine kinase]~~, ~~with EC number~~ [~~http://www.brenda~~-~~enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2~~] </~~span~~></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tpd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tpd OCA], [https://pdbe.org/6tpd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tpd RCSB], [https://www.ebi.ac.uk/pdbsum/6tpd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tpd ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=6tpd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tpd OCA], [~~http~~://pdbe.org/6tpd PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6tpd RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6tpd PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6tpd ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/JAK2_HUMAN JAK2_HUMAN]] Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6. Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BDCHS) [MIM:[~~http~~://omim.org/entry/600880 600880]]. A syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera. Defects in JAK2 are a cause of polycythemia vera (PV) [MIM:[~~http~~://omim.org/entry/263300 263300]]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.<ref>PMID:15781101</ref> <ref>PMID:15793561</ref> <ref>PMID:15858187</ref> <ref>PMID:16603627</ref> Defects in JAK2 gene may be the cause of thrombocythemia type 3 (THCYT3) [MIM:[~~http~~://omim.org/entry/614521 614521]]. A myeloproliferative disorder characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.<ref>PMID:16325696</ref> <ref>PMID:22397670</ref> Defects in JAK2 are a cause of myelofibrosis (MYELOF) [MIM:[~~http~~://omim.org/entry/254450 254450]]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension. Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:[~~http~~://omim.org/entry/601626 601626]]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.<ref>PMID:16247455</ref>	+	[https://www.uniprot.org/uniprot/JAK2_HUMAN JAK2_HUMAN] Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6. Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BDCHS) [MIM:[https://omim.org/entry/600880 600880]. A syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera. Defects in JAK2 are a cause of polycythemia vera (PV) [MIM:[https://omim.org/entry/263300 263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.<ref>PMID:15781101</ref> <ref>PMID:15793561</ref> <ref>PMID:15858187</ref> <ref>PMID:16603627</ref> Defects in JAK2 gene may be the cause of thrombocythemia type 3 (THCYT3) [MIM:[https://omim.org/entry/614521 614521]. A myeloproliferative disorder characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.<ref>PMID:16325696</ref> <ref>PMID:22397670</ref> Defects in JAK2 are a cause of myelofibrosis (MYELOF) [MIM:[https://omim.org/entry/254450 254450]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension. Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:[https://omim.org/entry/601626 601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.<ref>PMID:16247455</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/JAK2_HUMAN JAK2_HUMAN]] Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.<ref>PMID:12023369</ref> <ref>PMID:19783980</ref> <ref>PMID:20098430</ref> <ref>PMID:21423214</ref>	+	[https://www.uniprot.org/uniprot/JAK2_HUMAN JAK2_HUMAN] Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.<ref>PMID:12023369</ref> <ref>PMID:19783980</ref> <ref>PMID:20098430</ref> <ref>PMID:21423214</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 6tpd" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6tpd" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Janus kinase 3D structures\|Janus kinase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	~~[[Category: Non-specific protein-tyrosine kinase]]~~	+	[[Category: Burhardt MN]]
-	[[Category: Burhardt~~, M N~~]]	+	[[Category: Carnerup MA]]
-	[[Category: Carnerup~~, M A~~]]	+	[[Category: Hansen BB]]
-	[[Category: Hansen~~, B B~~]]	+	[[Category: Jepsen TJ]]
-	[[Category: Jepsen~~, T J~~]]	+	[[Category: Jerre A]]
-	[[Category: Jerre, A]]	+	[[Category: Larsen J]]
-	[[Category: Larsen, J]]	+	[[Category: Larsen M]]
-	[[Category: Larsen, M]]	+	[[Category: Moelck C]]
-	[[Category: Moelck, C]]	+	[[Category: Nasipireddy VR]]
-	[[Category: Nasipireddy~~, V R~~]]	+	[[Category: Rai S]]
-	[[Category: Rai, S]]	+	[[Category: Ritzen A]]
-	[[Category: Ritzen, A]]	+	[[Category: Seitzberg JG]]
-	[[Category: Seitzberg~~, J G~~]]	+	[[Category: Sindet R]]
-	[[Category: Sindet, R]]	+	[[Category: Vifian T]]
-	[[Category: Vifian, T]]	+
-	~~[[Category: Complex]]~~	+
-	~~[[Category: Inhibitor]]~~	+
-	~~[[Category: Transferase~~]]	+

OCA at 11:34, 22 July 2020

OCA — Wed, 22 Jul 2020 11:34:25 GMT

←Older revision		Revision as of 11:34, 22 July 2020
Line 1:		Line 1:

	==Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity==		==Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity==
-	<StructureSection load='6tpd' size='340' side='right'caption='[[6tpd]]' scene=''>	+	<StructureSection load='6tpd' size='340' side='right'caption='[[6tpd]], [[Resolution\|resolution]] 1.99Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TPD OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TPD FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6tpd]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TPD OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TPD FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tpd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tpd OCA], [http://pdbe.org/6tpd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tpd RCSB], [http://www.ebi.ac.uk/pdbsum/6tpd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tpd ProSAT]</span></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=QZ8:3-methyl-4-phenyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one'>QZ8</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">JAK2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tpd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tpd OCA], [http://pdbe.org/6tpd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tpd RCSB], [http://www.ebi.ac.uk/pdbsum/6tpd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tpd ProSAT]</span></td></tr>
	</table>		</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/JAK2_HUMAN JAK2_HUMAN]] Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6. Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BDCHS) [MIM:[http://omim.org/entry/600880 600880]]. A syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera. Defects in JAK2 are a cause of polycythemia vera (PV) [MIM:[http://omim.org/entry/263300 263300]]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.<ref>PMID:15781101</ref> <ref>PMID:15793561</ref> <ref>PMID:15858187</ref> <ref>PMID:16603627</ref> Defects in JAK2 gene may be the cause of thrombocythemia type 3 (THCYT3) [MIM:[http://omim.org/entry/614521 614521]]. A myeloproliferative disorder characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.<ref>PMID:16325696</ref> <ref>PMID:22397670</ref> Defects in JAK2 are a cause of myelofibrosis (MYELOF) [MIM:[http://omim.org/entry/254450 254450]]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension. Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:[http://omim.org/entry/601626 601626]]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.<ref>PMID:16247455</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/JAK2_HUMAN JAK2_HUMAN]] Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.<ref>PMID:12023369</ref> <ref>PMID:19783980</ref> <ref>PMID:20098430</ref> <ref>PMID:21423214</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Herein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fragment-based lead generation efforts. A two-stage strategy was chosen with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose pocket-targeting substituent was followed by the introduction of a variety of P-loop-targeting functional groups. Combining the best moieties from both stages of the optimization afforded compound 40, which showed excellent potency and selectivity. Metabolism studies in vitro and in vivo together with an in vitro safety evaluation suggest that 40 may be a viable lead compound for the development of highly subtype-selective JAK1 inhibitors.
		+
		+	Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.,Hansen BB, Jepsen TH, Larsen M, Sindet R, Vifian T, Burhardt MN, Larsen J, Seitzberg JG, Carnerup MA, Jerre A, Molck C, Lovato P, Rai S, Nasipireddy VR, Ritzen A J Med Chem. 2020 Jun 8. doi: 10.1021/acs.jmedchem.0c00359. PMID:32462873<ref>PMID:32462873</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6tpd" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Burhardt MN]]	+	[[Category: Non-specific protein-tyrosine kinase]]
-	[[Category: Carnerup MA]]	+	[[Category: Burhardt, M N]]
-	[[Category: Hansen BB]]	+	[[Category: Carnerup, M A]]
-	[[Category: Jepsen TJ]]	+	[[Category: Hansen, B B]]
-	[[Category: Jerre A]]	+	[[Category: Jepsen, T J]]
-	[[Category: Larsen J]]	+	[[Category: Jerre, A]]
-	[[Category: Larsen M]]	+	[[Category: Larsen, J]]
-	[[Category: Moelck C]]	+	[[Category: Larsen, M]]
-	[[Category: Nasipireddy VR]]	+	[[Category: Moelck, C]]
-	[[Category: Rai S]]	+	[[Category: Nasipireddy, V R]]
-	[[Category: Ritzen A]]	+	[[Category: Rai, S]]
-	[[Category: Seitzberg JG]]	+	[[Category: Ritzen, A]]
-	[[Category: Sindet R]]	+	[[Category: Seitzberg, J G]]
-	[[Category: Vifian T]]	+	[[Category: Sindet, R]]
		+	[[Category: Vifian, T]]
		+	[[Category: Complex]]
		+	[[Category: Inhibitor]]
		+	[[Category: Transferase]]

OCA at 06:26, 10 June 2020

OCA — Wed, 10 Jun 2020 06:26:21 GMT

←Older revision		Revision as of 06:26, 10 June 2020
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6tpd ~~is ON HOLD until Paper Publication~~	+	==Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity==
-		+	<StructureSection load='6tpd' size='340' side='right'caption='[[6tpd]]' scene=''>
-	~~Authors~~: ~~Hansen, B~~.B.~~, Jepsen, T~~.J.~~, Larsen, M~~.~~, Sindet, R~~.~~, Vifian, T~~.~~, Burhardt, M~~.N., ~~Larsen, J~~.~~, Seitzberg, J~~.G., ~~Carnerup~~, M.A.~~, Jerre, A~~., ~~Moelck, C~~.~~, Rai, S~~., ~~Nasipireddy, V~~.~~R., Ritzen, A~~.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TPD OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TPD FirstGlance]. <br>
-	~~Description: Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity~~	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tpd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tpd OCA], [http://pdbe.org/6tpd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tpd RCSB], [http://www.ebi.ac.uk/pdbsum/6tpd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tpd ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	</table>
-	[[Category: ~~Nasipireddy, V.R~~]]	+	__TOC__
-	[[Category: ~~Rai, S~~]]	+	</StructureSection>
-	[[Category: ~~Jepsen, T.J~~]]	+	[[Category: Large Structures]]
-	[[Category: ~~Larsen, J~~]]	+	[[Category: Burhardt MN]]
-	[[Category: ~~Vifian, T~~]]	+	[[Category: Carnerup MA]]
-	[[Category: ~~Hansen, B.B~~]]	+	[[Category: Hansen BB]]
-	[[Category: ~~Ritzen, A~~]]	+	[[Category: Jepsen TJ]]
-	[[Category: ~~Larsen, M~~]]	+	[[Category: Jerre A]]
-	[[Category: ~~Moelck, C~~]]	+	[[Category: Larsen J]]
-	[[Category: ~~Jerre, A~~]]	+	[[Category: Larsen M]]
-	[[Category: ~~Burhardt, M.N~~]]	+	[[Category: Moelck C]]
-	[[Category: ~~Sindet, R~~]]	+	[[Category: Nasipireddy VR]]
-	[[Category: ~~Seitzberg, J.G~~]]	+	[[Category: Rai S]]
-	[[Category: ~~Carnerup, M.A~~]]	+	[[Category: Ritzen A]]
		+	[[Category: Seitzberg JG]]
		+	[[Category: Sindet R]]
		+	[[Category: Vifian T]]

OCA: Protected "6tpd" [edit=sysop:move=sysop]

OCA — Wed, 25 Dec 2019 07:17:54 GMT

Protected "6tpd" [edit=sysop:move=sysop]

←Older revision

Revision as of 07:17, 25 December 2019

OCA: New page: '''Unreleased structure''' The entry 6tpd is ON HOLD until Paper Publication Authors: Hansen, B.B., Jepsen, T.J., Larsen, M., Sindet, R., Vifian, T., Burhardt, M.N., Larsen, J., Seitzbe...

OCA — Wed, 25 Dec 2019 07:17:52 GMT

New page: '''Unreleased structure''' The entry 6tpd is ON HOLD until Paper Publication Authors: Hansen, B.B., Jepsen, T.J., Larsen, M., Sindet, R., Vifian, T., Burhardt, M.N., Larsen, J., Seitzbe...

New page

'''Unreleased structure'''

The entry 6tpd is ON HOLD until Paper Publication

Authors: Hansen, B.B., Jepsen, T.J., Larsen, M., Sindet, R., Vifian, T., Burhardt, M.N., Larsen, J., Seitzberg, J.G., Carnerup, M.A., Jerre, A., Moelck, C., Rai, S., Nasipireddy, V.R., Ritzen, A.

Description: Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity
[[Category: Unreleased Structures]]
[[Category: Nasipireddy, V.R]]
[[Category: Rai, S]]
[[Category: Jepsen, T.J]]
[[Category: Larsen, J]]
[[Category: Vifian, T]]
[[Category: Hansen, B.B]]
[[Category: Ritzen, A]]
[[Category: Larsen, M]]
[[Category: Moelck, C]]
[[Category: Jerre, A]]
[[Category: Burhardt, M.N]]
[[Category: Sindet, R]]
[[Category: Seitzberg, J.G]]
[[Category: Carnerup, M.A]]